ICD-10 Coding for Lymphosarcoma(C83.30, C85.90)
Complete ICD-10-CM coding and documentation guide for Lymphosarcoma. Includes clinical validation requirements, documentation requirements, and coding pitfalls.
Also known as:
Related ICD-10 Code Ranges
Complete code families applicable to Lymphosarcoma
Code Comparison: When to Use Each Code
Compare key differences between these codes to ensure accurate selection
| Code | Description | When to Use | Key Documentation |
|---|---|---|---|
| C83.30 | Mantle cell lymphoma, unspecified site | Use when mantle cell lymphoma is confirmed but the site is unspecified. |
|
| C85.90 | Non-Hodgkin lymphoma, unspecified, unspecified site | Use when the subtype of non-Hodgkin lymphoma is unclear. |
|
Clinical Decision Support
Always review the patient's clinical documentation thoroughly. When in doubt, choose the more specific code and ensure documentation supports it.
Key Information: ICD-10 code for lymphosarcoma
Essential facts and insights about Lymphosarcoma
Primary ICD-10-CM Codes for lymphosarcoma
Decision Criteria
clinical Criteria
- Histological confirmation with specific immunohistochemistry markers
Applicable To
- Lymphosarcoma equivalent
Excludes
- Chronic lymphocytic leukemia (CLL)
Clinical Validation Requirements
- CD5+, CD20+, cyclin D1+ immunohistochemistry
Code-Specific Risks
- Misclassification if subtype is not confirmed
Coding Notes
- Ensure histological confirmation before coding.
C85.90 - Non-Hodgkin lymphoma, unspecified, unspecified site
Use when the subtype of non-Hodgkin lymphoma is unclear.
Applicable To
- Aggressive B-cell lymphoma, not further classified
Excludes
- Specific subtypes of non-Hodgkin lymphoma
Clinical Validation Requirements
- Biopsy report lacking molecular studies
Coding Notes
Avoid using this code if specific subtype information is available.
Ancillary Codes
Additional codes that should be used in conjunction with the main diagnosis codes when applicable.
Differential Codes
Alternative codes to consider when ruling out similar conditions to the primary diagnosis.
Documentation & Coding Risks
Avoid these common documentation and coding issues when documenting Lymphosarcoma to ensure proper reimbursement, maintain compliance, and reduce audit risk. These guidelines are particularly important when using ICD-10 code C83.30.
Impact
Clinical: May affect treatment decisions., Regulatory: Non-compliance with coding standards., Financial: Potential for incorrect reimbursement.
Mitigation Strategy
Ensure thorough review of pathology reports, Consult with oncologist for subtype confirmation
Impact
Reimbursement: May lead to incorrect DRG assignment and financial loss., Compliance: Non-compliance with coding guidelines., Data Quality: Decreases accuracy of clinical data.
Mitigation Strategy
Use the specific subtype code if available.
Impact
High risk of audit if subtype is not documented.
Mitigation Strategy
Ensure all pathology reports are reviewed and subtype is documented.
Documentation errors, coding pitfalls, and audit risks are interconnected aspects of medical coding and billing. Addressing all three areas helps ensure accurate coding, optimal reimbursement, and regulatory compliance.
Frequently Asked Questions
Common questions about ICD-10 coding for Lymphosarcoma, with expert answers to help guide accurate code selection and documentation.
Documentation Templates for Lymphosarcoma
Use these documentation templates to ensure complete and accurate documentation for Lymphosarcoma. These templates include all required elements for proper coding and billing.
Oncology Progress Note
Specialty: OncologyRequired Elements
- Diagnostic statement
- Treatment rationale
- Histological findings
Example Documentation
Examples: Poor vs. Good Documentation
Poor Documentation Example
Good Documentation Example
Explanation
Need help with ICD-10 coding for Lymphosarcoma? Ask your questions below.